Context: Recurrence of hypercortisolism in patients after bilateral adrenalectomy for Cushing disease is extremely rare.
Patient: We present a 27-year-old man who previously underwent bilateral adrenalectomy for Cushing disease with complete clinical resolution. Cushingoid features recurred 12 years later, with bilateral testicular enlargement. Hormonal tests confirmed adrenocorticotropic hormone (ACTH)-dependent Cushing disease. Surgical resection of the testicular tumors led to clinical and biochemical remission.
Design and Results:
Gene expression analysis of the tumor tissue by quantitative polymerase chain reaction showed high expression of all key steroidogenic enzymes. Adrenocortical-specific genes were 5.1 3 10 5 (CYP11B1), 1.8 3 10 2 (CYP11B2), and 6.3 3 10 4 (MC2R) times higher than nonsteroidogenic fibroblast control. This correlated with urine steroid metabolome profiling showing 2 fivefold increases in the excretion of the metabolites of 11-deoxycortisol, 21-deoxycortisol, and total glucocorticoids. Leydig-specific genes were 4.3 3 10 1 (LHCGR) and 9.3 3 10 0 (HSD17B3) times higher than control, and urinary steroid profiling showed twofold increased excretion of the major androgen metabolites androsterone and etiocholanolone. These distinctly increased steroid metabolites were suppressed by dexamethasone but unresponsive to human chorionic gonadotropin stimulation, supporting the role of ACTH, but not luteinizing hormone, in regulating tumor-specific steroid excess.
Conclusion:
We report bilateral testicular tumors occurring in a patient with recurrent Cushing disease 12 years after bilateral adrenalectomy. Using mRNA expression analysis and steroid metabolome profiling, the tumors demonstrated both adrenocortical and gonadal steroidogenic properties, similar to testicular adrenal rest tumors found in patients with congenital adrenal hyperplasia, suggesting the presence of pluripotent cells even in patients without congenital adrenal hyperplasia. (J Clin Endocrinol Metab 102: 339-344, 2017) B ilateral adrenalectomy is considered a definitive cure for Cushing disease, but some patients may have residual adrenal function from postsurgical remnants or ectopic adrenal tissue (1, 2) . Rarely, patients with Nelson syndrome [and high adrenocorticotropic hormone (ACTH) levels] after bilateral adrenalectomy have been reported to develop testicular tumors, with variable cortisol and androgen production (3) (4) (5) . Some tumors were removed due to symptoms of mass effects, but detailed molecular investigations were not conducted.
In contrast, testicular adrenal rest tumors (TARTs) are seen in up to 94% of male patients with congenital adrenal hyperplasia (CAH), with increasing prevalence during adolescence (6, 7) . Elevated ACTH levels, and possibly luteinizing hormone (LH), may play a role in its development (8) . We recently demonstrated that TARTs have both adrenocortical and Leydig cell features, suggesting a pluripotent embryonic cell origin (9) . We report a rare case of bilateral testicular tumors resulting in recurrent hypercortisolism in a patient with Cushing disease who had previously undergone bilateral adrenalectomy. We characterized the steroidogenic potential of these tumors by mRNA expression analysis and serum and urinary steroid profiling. Our findings demonstrate that the tumor tissue featured both adrenal and gonadal steroidogenic properties, resembling TART tissue found in patients with CAH.
Case Report
An 11-year-old boy presented with rapid weight gain, rounded facies, and abdominal striae. He was diagnosed with Cushing disease and underwent transsphenoidal removal of a corticotrophin-producing pituitary adenoma. Recurrence occurred within the first postoperative year. After failure of radiotherapy and ketoconazole to control his symptoms, he underwent bilateral adrenalectomy 4 years later (age 15 years), resulting in undetectable serum cortisol after ACTH stimulation (,20 nmol/L). Spontaneous pubertal development ensued. c Dexamethasone was administrated orally as 2 mg every 6 h for 48 h, with investigations done at 8 AM on the third day, 6 h after last dose.
d Daily intramuscular injections of 1500 U hCG were administered subcutaneously on 3 consecutive days at 8 AM.
e Taken 1 wk after surgery, 24 h after last hydrocortisone dose.
f Levels not taken due to inadequate serum volume collected.
g Cortisol levels were measured with immunoassay. Other cortisol levels were measured with liquid chromatography-tandem mass spectrometry. At the age of 27 years, 12 years postadrenalectomy, he experienced increased lethargy and weight gain over a period of 6 months. He had a Cushingoid habitus and abdominal striae. His testes were nodular, hard, and enlarged bilaterally. Corticosteroid replacement was stopped, and recurrent ACTH-dependent Cushing disease was confirmed biochemically (Table 1) . Magnetic resonance imaging showed a small, stable pituitary remnant. Ultrasound and magnetic resonance imaging of the testes revealed a single, large right testicular tumor and multiple left testicular tumors with a small remnant of normal tissue [ Fig. 1(A) and 1(B) ]. Abdominal CT showed a small nodule (,1 cm) in the left adrenal region, suggesting incomplete surgical resection or postsurgical scar tissue. Semen analysis showed azoospermia.
The patient underwent bilateral testicular nodulectomy, with preservation of his left residual normal testicular tissue [ Fig. 1(C) and 1(D) ]. One week after surgery, earlymorning (8 AM) cortisol was undetectable (,20 nmol/L) ( Table 1) . His symptoms resolved, and he was started on corticosteroid and testosterone replacement.
Materials and Methods
A detailed description of the materials and methods is provided in the Supplemental Materials and Methods. Written informed consent with permission for publication was obtained from the patient, and the study was approved by the local ethics committee.
Results
Serum and urine steroid metabolite profiling before and after surgery Serum and urine were collected at baseline, after highdose dexamethasone suppression test (HDDST), and after human chorionic gonadotropin (hCG) stimulation. Serum cortisol and its precursors (11-deoxycortisol and 17-hydroxyprogesterone) and androstenedione were elevated at baseline, suppressed by HDDST, and unresponsive to hCG stimulation (Table 1) . Levels were undetectable after surgery. Testicular vein sampling performed during surgery demonstrated excess steroid production bilaterally (Table 1) .
Urine steroid metabolite profiling [ Fig. 1(E) ] showed increased excretion of glucocorticoid metabolites, androgen metabolites (etiocholanolone), and precursor steroid metabolites from all three steroidogenic pathways. The metabolites of 11-deoxycortisol and 21-deoxycortisol were increased up to fivefold, and 17-hydroxyprogesterone metabolites were increased .10-fold of the upper reference range. Dehydroepiandrosterone, which is reflective of the classic androgen synthesis pathway, was low. In contrast, there was highly increased excretion of the alternative androgen pathway intermediates 3a,5a-17-hydroxyprogesterone [485 mg/24 h; control group median, 26 (range, 5 to 118) mg/24 h and 11-hydroxy-androsterone [15,766 mg/24 h; control group median, 588 (range, 181 to 1290) mg/24 h].
By comparison, urine steroid metabolite profiling of two newly diagnosed and hence untreated adolescent patients with 21-hydroxylase deficiency demonstrated a similar pattern of increased steroid metabolites, in particular those derived from progesterone, 17-hydroxyprogesterone, 21-deoxycortisol, and the alternative pathway metabolites 3a,5a-17-hydroxyprogesterone and 11beta-hydroxy-androsterone. Conversely, these changes were not observed in two adult patients with Cushing disease, who predominantly excreted increased amounts of corticosterone, 11-deoxycortisol, and, in particular, cortisol metabolites [ Fig. 1(E) ]. Thus, the steroid excretion pattern observed in our patient resembled a combination of CAH and Cushing disease.
Gene expression analysis of right testicular tumor tissue
Using quantitative polymerase chain reaction [ Fig.  1(F) ], the expressions of adrenal cortex-specific genes determined to be 5.1 3 10 5 (CYP11B1), 1.8 3 10 2 (CYP11B2), and 6.3 3 10 4 (MC2R) times higher in the patient's tumor tissue compared with the nonsteroidogenic control (fibroblast), whereas the expression for AGTR2 was 2 times lower. Genes common to both adrenal and testis tissue were 3.8 3 10 5 (CYP17A1) and 2.1 3 10 4 (HSD3B2) times higher, and Leydig cell genes were 4.3 3 10 1 (LHCGR) and 9.3 (HSD17B3) times higher compared with nonsteroidogenic control. Compared with TART samples from patients with CAH that we had previously similarly analyzed (9), the patient's tumor was above the interquartile range for glucocorticoid-related factors (CYP11B1, MC2R) and below the interquartile range for androgen-related factors (LHCGR, and HSD17B3).
Discussion
In this rare case of bilateral testicular tumors causing recurrence of Cushing disease after bilateral adrenalectomy, we were able to demonstrate by gene expression and steroid metabolome studies that the tumor tissue has shared adrenocortical and gonadal steroidogenic properties. TARTs are historically considered to originate from adrenal rests descending together with the testes during embryonic development (8) . However, we recently found evidence that they develop from pluripotent cells within the testes with adrenal and Leydig cell features (9) . Our patient's tumor shared morphological and biochemical features with adrenal tissue, Leydig cell tumors, and virilizing adrenocortical tumors, illustrating the difficulty of differentiating adrenocortical cells from Leydig cells.
In a previous similar case, Hamwi (10) demonstrated via in vitro studies that the testicular tumor in a patient with recurrent Cushing disease was able to produce cortisol and cortisone, although it did not produce androgens. We now demonstrate expression of adrenalspecific genes in the tumor tissue and have correlated this with increased glucocorticoid excretion. In addition, androgen excretion from both classic and alternative synthesis pathways (11, 12) was significantly increased, although relative gene expression of Leydig cell-specific genes was only slightly increased. Interestingly, the steroid excretion profile of the TART tumor in this patient resembled a combination of steroid excretion in CAH and Cushing disease with ACTH-mediated stimulation of intact steroidogenesis.
It is postulated that chronically elevated ACTH, LH, and angiotensin II contribute to differentiation of the early cell (even prenatally) and TART development (8, 13, 14) . In our patient, the response to dexamethasone and the high MC2R expression support the role of ACTH, which was persistently elevated. However, in this case, exposure was only postnatal, suggesting the presence of pluripotent cells within the testes also in postnatal life and adulthood. Conversely, no cases of postbilateral adrenalectomy TART development have been described in adults older than 23 years, suggesting that regression of pluripotent cells ensues shortly after puberty.
There was relatively higher expression of CYP11B1 and MC2R but lower expression of HSD17B3 and LHCGR compared with TARTs in patients with CAH (9). This suggests that our patient's tumor was more adrenal like, whereas TARTs in patients with CAH are more Leydig cell like, similar to other findings (3, 10) . It has also been suggested that an LH surge during puberty is important for TART development and progression in patients with CAH (6). Although our patient had low relative expression of LHCGR and no response to hCG, he entered into puberty soon after adrenalectomy, where he was exposed to high LH levels. Hence, it remains conceivable that early prepubertal LH stimulation of testicular tissue contributed to TART development.
In conclusion, we present a rare case of recurrent Cushing disease after bilateral adrenalectomy from testicular tumors with adrenal and Leydig cell-specific features. Endocrinologists should consider this possibility if symptoms recur after adrenalectomy while patients are on maintenance steroids. Further research is needed to understand the mechanism of development of these testicular tumors.
